We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+5.67%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.78B
AUM Growth
–
Cap. Flow
+$4.65B
Cap. Flow
% of AUM
97.21%
Top 10 Holdings %
Top 10 Hldgs %
14.27%
Holding
616
New
605
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$91.9M |
| 2 |
CELG
Celgene Corp
CELG
|
+$79.7M |
| 3 |
Apple
AAPL
|
+$78.2M |
| 4 |
Qualcomm
QCOM
|
+$73.5M |
| 5 |
Amgen
AMGN
|
+$71.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.38% |
| 2 | Financials | 14.02% |
| 3 | Technology | 12.7% |
| 4 | Industrials | 8.01% |
| 5 | Energy | 6.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
NiSource
NI
$22.4B
| $2.99M | 0.06% |
+179,466
| New | +$2.92M |
|
|
IMGN
302
DELISTED
Immunogen Inc
IMGN
| $2.96M | 0.06% |
+485,000
| New | +$4.44M |
|
303
BCE
BCE
$19.9B
| $2.88M | 0.06% |
+62,632
| New | +$2.81M |
|
304
US Bancorp
USB
$99.6B
| $2.87M | 0.06% |
+63,744
| New | +$2.74M |
|
|
YHOO
305
DELISTED
Yahoo Inc
YHOO
| $2.86M | 0.06% |
+56,707
| New | +$2.67M |
|
306
Expedia Group
EXPE
$31.2B
| $2.83M | 0.06% |
+33,103
| New | +$2.81M |
|
307
Agios Pharmaceuticals
AGIO
$2.16B
| $2.8M | 0.06% |
+25,000
| New | +$2.23M |
|
|
SPPI
308
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $2.77M | 0.06% |
+400,000
| New | +$2.94M |
|
309
Halozyme
HALO
$9.72B
| $2.75M | 0.06% |
+285,000
| New | +$2.53M |
|
310
Cencora
COR
$60.3B
| $2.75M | 0.06% |
+30,494
| New | +$2.61M |
|
311
T-Mobile US
TMUS
$193B
| $2.75M | 0.06% |
+102,001
| New | +$2.82M |
|
312
iShares MSCI Emerging Markets ETF
EEM
$28B
| $2.7M | 0.06% |
+68,982
| New | +$2.8M |
|
313
Zions Bancorporation
ZION
$10.1B
| $2.68M | 0.06% |
+94,149
| New | +$2.66M |
|
|
CTIC
314
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $2.65M | 0.06% |
+112,500
| New | +$2.6M |
|
315
Puma Biotechnology
PBYI
$406M
| $2.65M | 0.06% |
+14,000
| New | +$3.11M |
|
316
Altria Group
MO
$122B
| $2.59M | 0.05% |
+52,554
| New | +$2.56M |
|
|
UN
317
DELISTED
Unilever NV New York Registry Shares
UN
| $2.58M | 0.05% |
+66,000
| New | +$2.58M |
|
318
Celldex Therapeutics
CLDX
$2.77B
| $2.56M | 0.05% |
+9,333
| New | +$2.32M |
|
319
Ovintiv
OVV
$17.5B
| $2.55M | 0.05% |
+36,554
| New | +$3.11M |
|
|
RDUS
320
DELISTED
Radius Health, Inc.
RDUS
| $2.53M | 0.05% |
+65,000
| New | +$1.54M |
|
321
Phillips 66
PSX
$82.9B
| $2.52M | 0.05% |
+35,174
| New | +$2.6M |
|
322
Adobe
ADBE
$89.5B
| $2.52M | 0.05% |
+34,623
| New | +$2.43M |
|
323
HCA Healthcare
HCA
$84.8B
| $2.48M | 0.05% |
+33,824
| New | +$2.38M |
|
324
Leggett & Platt
LEG
$1.52B
| $2.47M | 0.05% |
+58,056
| New | +$2.29M |
|
325
APA Corp
APA
$12.8B
| $2.46M | 0.05% |
+39,262
| New | +$2.79M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for Candriam SCA, which disclosed 616 positions worth $4.78B. Its ten largest holdings account for 14% of the portfolio.
Its largest position is Gilead Sciences: 888,125 shares worth $83.7M.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, followed by Financials and Technology.
- Candriam SCA's largest Q4 2014 buy was Gilead Sciences: 888,125 shares worth $83.7M.
- Candriam SCA's ten largest holdings make up 14% of its $4.78B portfolio in Q4 2014.
- Candriam SCA disclosed 616 positions in Q4 2014, its first 13F filing on record.
Based on Candriam SCA's 13F filing for Q4 2014, filed 26 Mar 2015.